Medical-dictionary-0-9
From WikiMD's Wellness Encyclopedia
WikiMD's dictionary of medicine is a collaborative effort to develop a resource designed to provide clear, concise definitions and articles on medical terms. It serves as an essential reference for both patients and healthcare professionals, students, and anyone looking to deepen their understanding of medical science. From complex conditions to basic anatomy, the dictionary covers a vast range of topics.
Medical-dictionary-0-9[edit source]
- (+)-Naloxone
- (Un)well
- ...First Do No Harm
- 0 hospital admission
- 0 pad per day
- 0-10 s walking
- 1 - 2 days
- 1 - never affects sleep
- 1 - normal, no complaint
- 1 3 lymph nodes positive
- 1 np
- 1 pad per day
- 1,2 dimethylhydrazine dihydrochloride
- 1,4-Butanediol
- 1-2 1/2 hours
- 1-2 hospital admissions
- 1-3 lymph nodes positive
- 1-7 days
- 1-Testosterone
- 1/2 gallon
- 1/2 l
- 1/2 pint
- 10 pack
- 100K Pathogen Genome Project
- 100K Wellness Project
- 10p11.1
- 10p11.21
- 10p11.23
- 10p12.1
- 10p12.3 p11.2
- 10p12.3 rearrangement
- 10p12.31
- 10q11.1
- 10q11.21
- 10q23 (pten locus) deletion analysis performed
- 10q23 q24
- 10q23.2 q23.33
- 10q24 q25
- 10q24.1 q24.3
- 10q24.31
- 10q25.1
- 10q25.3 q26.1
- 10q25.3
- 10q26.13 q26.3
- 10q26.13
- 10q26.2
- 10th growth percentile
- 11 pack
- 11-20 s walking
- 11-Hydroxy-THC
- 11-Nor-9-carboxy-THC
- 111in-pertuzumab
- 11c-sarcosine
- 11p11.2 p11.1
- 11p12 p11.2
- 11p13 p12
- 11p14.3
- 11p15 rearrangement
- 11p15.1
- 11p15.2
- 11p15.5 p15.4
- 11q terminal deletion disorder
- 11q12 q13
- 11q12.1
- 11q12.2
- 11q13.2
- 11q13.3 q13.5
- 11q13.4
- 11q14.1
- 11q14.2 q14.3
- 11q14.2
- 11q22.2 q22.3
- 11q23 anomaly
- 11q23 q24
- 11q23.1 q23.2
- 11q23.1 q23.3
- 11q23.2 q23.3
- 11q24 q24
- 11q24 q25
- 12 hydroxyeicosatetraenoic acid
- 12 lead 1 lead missing
- 12 lead cabrera
- 12 lead continuous ecg
- 12 lead easi dower transformation
- 12 lead ecg extracted from 12 lead continuous ecg recording
- 12 lead mason likar
- 12 lead modified mason likar
- 12 lead non standard
- 12 lead single pad
- 12 lead standard
- 12 lead unspecified
- 123i ibzm
- 124i fiau
- 124i-a11 psca minibody
- 124i-labeled albumin
- 125-I deoxyuridine
- 129/sv
- 12b and mgit
- 12p11.2
- 12p12.1 p11.2
- 12p13 p12.3
- 12p13 p12
- 12p13.1 p12.3
- 12p13.1 p12
- 12p13.2 p12.3
- 12p13.2 rearrangement
- 12p13.3
- 12q gain
- 12q12 q14
- 12q13 q15
- 12q13.13
- 12q13.3
- 12q14 q15
- 12q14.1
- 12q14.3
- 12q23 q24.1
- 12q23 q24
- 12q23.1
- 12q24.11
- 12q24.13
- 12q24.1
- 12q24.31
- 12th grade, no diploma
- 131 I ethiodized oil
- 131 cs
- 131i-tenatumomab
- 13c lycopene
- 13c phytoene
- 13c phytofluene
- 13c sodium octanoate
- 13q abnormality
- 13q deletion syndrome
- 13q11 q12
- 13q12 13
- 13q14.12 q14.2
- 13q14.1
- 14 Hours (2005 film)
- 14 c-labeled vemurafenib
- 14-3-3 protein
- 14-n/15-n metabolic labeling quantitation
- 14c eribulin acetate
- 14c pamiparib
- 14c-lenvatinib mesylate
- 14q11.1 q11.2
- 14q13.1
- 14q13.2
- 14q21 q24
- 14q23 q24.1
- 14q31 q32.1
- 14q32.1 q32.2
- 14q32.1
- 14q32.2
- 14q32.33
- 15gag proteinase
- 15o h2o
- 15q15.1 q21.1
- 15q15.3
- 15q21.1
- 15q22.3 q23
- 15q25
- 15q26.3
- 15q26
- 16-hydroxyestrogens
- 1650g
- 16k prl
- 16p11.2 12.1
- 16p11.2 p11.1
- 16p12.1
- 16p12.3
- 16p13.13 p13.12
- 16q12.2
- 16q13 q21
- 16q22.2 q22.3
- 16q24.1 q24.2
- 17 alpha-hydroxyprogesterone caproate
- 17 demethoxy 17 allylaminogeldanamycin mesylate
- 177 lu cc49
- 177lu-dtpa-omburtamab
- 177lu-pp-f11n
- 17p abnormality
- 17p11.1
- 17p11.2
- 17p12 17p11.2
- 17q11 q21
- 17q11.1
- 17q12 q21
- 17q21 microdeletion syndrome
- 17q21 q22
- 17q21.1 q21.3
- 17q21.2
- 17q21.3 q22.1
- 17q22 q23.2
- 17q24 q25
- 17q24.2
- 17q24.3
- 17q25.1
- 17q25.2 q25.3
- 17q25.3
- 17β-Hydroxysteroid dehydrogenase III deficiency
- 1890 Institutions
- 18f 6f dopamine
- 18f choline
- 18f dcfbc
- 18f fluoro ethyl l tyrosine
- 18f fpac
- 18f-al-nota-matbbn
- 18f-alfatide ii
- 18f-alphavbeta6-binding peptide
- 18f-ambf3-tate
- 18f-asis
- 18f-fluorobenzyl triphenyl phosphonium
- 18f-tetrafluoroborate
- 18ffacbc
- 18fffnp
- 18fspa rq
- 18p syndrome
- 18q11.1
- 18q12 q21
- 18q21.31
- 19 nor progesterone
- 19-Norandrosterone
- 1985 World Health Organization AIDS surveillance case definition
- 1994 Institutions
- 1994 expanded World Health Organization AIDS case definition
- 19p13.1 13.2
- 19p13.2 p13.1
- 19q13.13
- 19q13.31
- 19q13.32
- 19q13.41
- 19q13.42
- 19q13.4
- 1: I don't think about it at all
- 1: I never worry about it
- 1: it does not upset me at all
- 1: not at all afraid
- 1:99 Concert
- 1d10 antigen
- 1h imidazole
- 1h mqc mrsi
- 1p loss of heterozygosity
- 1p telomere deletion syndrome
- 1p/19q deletion analysis performed
- 1p13.3 p13.1
- 1p31.2 p31.1
- 1p32.3 p31.3
- 1p33 p32
- 1p33 p34
- 1p34 p33
- 1p35 p34.2
- 1p36.1 p35
- 1p36.2 p36.12
- 1p36.23 p35.1
- 1p36.3 p36.1
- 1pter p22.1
- 1q gain
- 1q12 q23
- 1q21 amplification
- 1q22 q23
- 1q25 q31.1
- 1q25.2 q25.3
- 1q31 q32
- 1q41 q42
- 1q41 q44
- 1q42.1 q42.2
- 1st trimester spontaneous abortion
- 2 (3 ethylureido) 6 methylpyridine
- 2 - mild complaints, but needs no assistance
- 2 - occasionally delays falling asleep
- 2 methylbutyryl coa dehydrogenase deficiency
- 2 methylethyleneimine
- 2 pads per day
- 2 sided test
- 2',3,4,4'-tetrahydroxy-chalcone
- 2+ score
- 2+
- 2,2,4,4-2h cholate
- 2,3 dichloro 4 (2 methylene 1 oxobutyl)phenoxyacetic acid
- 2,3'-bipyridine, 1,2,3,6-tetrahydro-, (s)- (9ci)
- 2,4,d/2,4,5,t
- 2,5-Dimethoxy-4-iodoamphetamine
- 2,6,10,14 tetramethylpentadecane
- 2-(3-ethylureido)-6-methylpyridine
- 2-13c acetate
- 2-4 activities required help
- 2-5a
- 2-Methoxyestradiol
- 2-d gel electrophoresis
- 2-dimensional biplane mode
- 2-dimensional single plane mode
- 2-hydroxyestrogens
- 2-mpp phosphopeptide-tetanus peptide vaccine
- 2-prime,5-prime-oligoadenylate synthetase, 69-kd gene;
- 20 pack
- 2000 Simpsonwood CDC conference
- 2004 California Proposition 71
- 2006 Missouri Amendment 2
- 2008 Kousseri vaccination campaign
- 2008 Michigan Proposal 2
- 2009 swine flu pandemic timeline
- 2012 Washington Initiative 502
- 20: very sick; requiring hospitalization
- 20p11.2
- 20q11.1 11.23
- 20q11.2 q13.1
- 20q12 q13.11
- 20q13.1 q13.2
- 20s proteosome
- 21 and a Wake-Up
- 21-ohd
- 212pb tcmc trastuzumab
- 21d tab
- 21q21.3
- 21q22.11
- 22q telomere deletion syndrome
- 22q11.1 q11.2
- 22q11.22
- 22q12.1 q13.2
- 22q13.2
- 22q13.33
- 239-9° C
- 24 flavors
- 24h ptu
- 25-50%
- 25B-NBOMe
- 25th growth percentile
- 26s proteosome
- 27 35(27l):mart 1
- 28d tab
- 2:1 atrioventricular block by ekg finding
- 2d flair
- 2d mode
- 2d pd/t2-weighted mri
- 2d t2-weighted
- 2d-rplc
- 2h postprandial glucose
- 2h postprandial insulin
- 2it bad monoclonal antibody 170
- 2nd trimester spontaneous abortion
- 2p12 p13
- 2p23.3 p23.2
- 2p24.3 q21.3
- 2p25 p24
- 2q11.2 q12
- 2q12 q14
- 2q22 q24
- 2q22.2 q23.3
- 2q23 q24
- 2q31.2 q33.1
- 2q32.2 q32.3
- 2q33 q37
- 2q35 q37
- 2q36 q37
- 2x-121 drug response prediction
- 3 - 4 days
- 3 - age-appropriate activity severely impaired
- 3 - frequently delays falling asleep
- 3 hsd inhibitor
- 3 hydroxyestra 1,3,5(10) trien 17 one
- 3 methylcrotonyl coa carboxylase deficiency
- 3 nbap
- 3 or more pads per day
- 3 pack
- 3' utr mutation
- 3'utr
- 3(r) (2 hydroxy 2,2 dithien 2 ylacetoxy)
- 3+ score
- 3,4,3',5'-tetrahydroxy-trans-stilbene
- 3,5-xylyl-methylcarbamate
- 3-4 (fibrous septa)
- 3-4 1/2 hours
- 3-Methoxymorphinan
- 3-beta hsd deficiency
- 3-dimensional mode
- 3-dimethylallyl-4,4'-dihydroxy-6-methoxychalcone
- 3-hsd inhibitor
- 3-hydroxy-2-methoxyestra-1,3,5(10)-trien-17-one
- 3-log reduction in philadelphia chromosome positive cells
- 30: severely disabled
- 31-60 minutes
- 34βE12
- 3D bioprinting
- 3DiTeams
- 3alpha,7alpha,12alpha-trihydroxy-5beta-cholanate
- 3ap/famp
- 3d air-liquid interface organoid
- 3d conformal accelerated partial breast irradiation
- 3d mode
- 3d mp rage
- 3d neurosphere
- 3d organoid
- 3d post-contrast t1-weighted ir-gre
- 3d pre-contrast t1-weighted ir-gre
- 3d
- 3h dt li
- 3hc
- 3m cavilon advanced skin protectant
- 3p loss of heterozygosity
- 3p12 q13.2
- 3p14 loh
- 3p26 p24
- 3q21 q23
- 3q25.1 q25.2
- 3q26.1 q26.2
- 3t mri
- 4 - confined to bed, needs nursing care
- 4 amino l (2 cyano 2 deoxy beta d arabinofuranosyl)
- 4 demethylcholesteryloxycarbonylpenclomedine
- 4 ipomeanol
- 4 nitroestrone 3 methyl ether
- 4 o tolylazo o toluidine
- 4 or more lymph nodes positive
- 4 pack
- 4 vinyl 1 cyclohexene dioxide
- 4' amino 6 hydroxyflavone
- 4'-amino-6-hydroxyflavone
- 4(1h)-pteridinone, 2-amino-6-(1,2,3-trihydroxypropyl)-
- 4+ score
- 4,4' methylenebisbenzenamine
- 4-H Youth Development Program
- 4-Nitroquinoline 1-oxide
- 40 kda proline-rich akt substrate
- 40: disabled; requires special care
- 45,X/46,XY mosaicism
- 46,XX/46,XY
- 46,xx disorders of sex development
- 46,xx ovarian dysgenesis
- 46,xx testicular disorders of sex development
- 46,xx true hermaphroditism
- 46,xx/46,xy disorders of sex development
- 46,xy disorders of sex development
- 46,xy true hermaphroditism
- 48, xxxy syndrome
- 48, xxyy syndrome
- 4ab t1e28z positive t-cells
- 4as treatment strategy
- 4d conformal radiation therapy
- 4d pet
- 4d
- 4kscore blood test
- 4q-tap block
- 4q12 q21
- 4q13.1 q21.1
- 4q22.1 q23
- 4q25 q31
- 4q26 q27
- 4q28 q32
- 4q34.1 q35.1
- 5 - 7 days
- 5 - needs intensive care, seriously ill, moribund
- 5 degrees c (+/-) 3 degrees c
- 5 fluoro 3 phenyl 2 ((s) 1 (9h purin 6 ylamino) propyl) 3h
- 5 fluoro pyrimidinone
- 5 mec
- 5 oxo l proline, 1r cis 3,3,5 trimethylcyclohexyl ester
- 5 oxo l proline, 1s cis 3,3,5 trimethylcyclohexyl ester
- 5 pack
- 5' untranslated regions
- 5' utr mutation
- 5'-end
- 5'utr
- 5-6 1/2 hours
- 5-8 activities required help
- 5-a-day program
- 5-androstane-3alpha,17beta-diol glucuronide
- 5-chlorodihydropyrimidine
- 5-fu regimen
- 5-nucleotidase
- 5-o-(3,4-dihydroxycinnamoyl)-l-quinic acid
- 50 hz noise
- 50-75%
- 50th growth percentile
- 5d itch
- 5d-itch
- 5p13 p12
- 5p13.1 p12
- 5q loss of heterozygosity
- 5q11.2 q13.2
- 5q12.1 q13.2
- 5q23 q32
- 5q23 q33
- 5q23.3 q31.1
- 5q31 q32
- 5q31.1 q33.1
- 5q34 q35
- 5th growth percentile
- 5th lumbar spinous process
- 5α-Reductase 2 deficiency
- 6 (o chlorophenyl) 7,10 dihydro 1 methyl 4h
- 6 15 centroblasts per high power field.
- 6 lead nehb-spori
- 6 lead standard
- 6 nc
- 6 pack
- 6 point agreement scale
- 6-30 minutes
- 6-Monoacetylmorphine
- 60 hz noise
- 609a
- 62cu-atsm
- 62cu-ethylglyoxal bis(thiosemicarbazone)
- 62cu-ptsm
- 64-cu-plerixafor
- 64cu-d(lgtflkc)
- 64cu-dotatate
- 64cu-nota-psma-peg-cy5.5-c' dot tracer
- 68ga-nota conjugated truncated form of evans blue
- 68ga-nota-3ptate-rgd
- 68ga-nota-nfb
- 68ga-psma-11-gadoxetate
- 6: I think about it all the time
- 6: I worry about it all the time
- 6: it makes me extremely upset
- 6: very afraid
- 6mhp vaccine
- 6p12 p11.1
- 6p21 p12
- 6p21.1 p12.2
- 6p21.3 p21.2
- 6q13 q21
- 6q16.1 q16.3
- 6q21 q22.1
- 6q21 q22.3
- 6q24 q25.1
- 6th
- 7 chloro 5 (2 chlorophenyl) 1, 3 dihydro 3 hydroxy 1,4
- 7 lead standard, non-human
- 7 pack
- 7-8 1/2 hours
- 7-Hydroxyamoxapine
- 75th growth percentile
- 7p13 p12
- 7p14 p12
- 7p15 p13
- 7p15 p14.2
- 7p21 p15
- 7p22 p21
- 7q31.1 q31.2
- 7q31.1 q31.3
- 7q33 q34
- 7q34 q35
- 7t mri
- 7th
- 7z compression format
- 8 lead standard
- 8 pack
- 8-Aminoquinoline
- 8-oxo-dg
- 89zr bevacizumab
- 89zr trastuzumab
- 89zr-dfo-fianlimab
- 89zr-dfo-mstp2109a
- 89zr-mmot0530a
- 89zr-nanocoll
- 89zr-pembrolizumab
- 8p21 p11.2
- 8p23 p22
- 8p23.2 p23.1
- 8q gain
- 8q21.3 q22
- 8q22.3 q23.1
- 8th
- 9 ethyl 6 mp
- 9 or more hours
- 9 pack
- 9-cis-epoxycarotenoid dioxygenase
- 90Y-DOTA-biotin
- 90th growth percentile
- 90y basiliximab
- 90y colloid
- 95th growth percentile
- 99mtc bone scintiscanning
- 99mtc gp
- 99mtc labeled albumin microspheres
- 9ac colloidal dispersion
- 9alpha,11beta-pgf2alpha
- 9h purine 6thio 98d
- 9p loss of heterozygosity
- 9p12 p11
- 9p21 loh
- 9p21 p12
- 9p21 p22
- 9p24.1
- 9q21 q22
- 9q22
- 9q31.3 q32
- 9q32 q33.3
- 9q32 q33
- 9q33 q34.1
- 9q33 q34
See also[edit source]
- Encyclopedia of Medicine
- List of Medical terms
- Cancer terms
- Drugs
- Cancer drugs
- Health topics
- Rare diseases
- List of lists
| Dictionary of medicine | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z |
| Special pages | |||||||||||||||||||||||||
| Misc. | 0-9 | Glossary | |||||||||||||||||||||||||
| Popular Glossaries | Dictionaries | Lists & Glossaries | Topics |
|---|---|---|---|
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
